GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Infections, Respiratory Tract
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT02257398
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT02254434
- Locations
- 🇲🇽
GSK Investigational Site, Mexico City, Mexico
Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
Phase 1
Completed
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02254447
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Other: ControlDietary Supplement: Test
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT02254460
- Locations
- 🇮🇳
GSK Investigational Site, Bangalore, India
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Phase 4
Completed
- Conditions
- Malaria VaccinesMalaria
- Interventions
- Procedure: Blood samplingDiagnostic Test: Assessment of body temperature
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54112
- Registration Number
- NCT02251704
- Locations
- 🇹🇿
GSK Investigational Site, Amani Tanga, Tanzania
The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
Phase 4
Completed
- Conditions
- Common Cold
- Interventions
- Other: PlaceboDrug: Test tablet
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 53
- Registration Number
- NCT02246166
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
Phase 1
Completed
- Conditions
- Anaemia
- Interventions
- Drug: GSK1278863
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT02243306
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluLaval™ QuadrivalentBiological: Fluzone® Quadrivalent
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2432
- Registration Number
- NCT02242643
- Locations
- 🇲🇽
GSK Investigational Site, Mexico city, Mexico
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1036
- Registration Number
- NCT02236611
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhalerDrug: SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhalerDrug: NEUMOTEX 400 (Budesonide 400 mcg)Drug: Salbutamol 100 mcg pMDI
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 239
- Registration Number
- NCT02233803
- Locations
- 🇦🇷
GSK Investigational Site, Rosario, Argentina
© Copyright 2025. All Rights Reserved by MedPath